14 completed, 4 terminated, 1 unknown, 1 withdrawn. 20 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 20 | Completed 14, Terminated 4, Unknown 1, Withdrawn 1 |
| Phase 2 | 1 | Completed 1 |
Follow Dac: new trials by email Literature Review of Dac trials Research Report on Dac
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Mutant p53-based Personalized Trial Using Decitabine and Arsenic Trioxide on AML/MDS Decitabine, Arsenic Trioxide - P53 Mutation, Myeloid Malignancy | Phase 1 | Unknown | Ruijin Hospital | 5 | 2018-01-10 | 2022-11-04 |
| Pacritinib and Chemotherapy in Treating Patients With Acute Myeloid Leukemia and FLT3 Mutations Pacritinib, Cytarabine, Daunorubicin Hydrochloride - Recurrent Adult Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia | Phase 1 | Completed | Bhavana Bhatnagar | 13 | 2016-01-12 | 2019-01-25 |
| Decitabine, Donor Natural Killer Cells, and Aldesleukin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia decitabine, natural killer cell therapy, aldesleukin - Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q) | Phase 1 | Completed | Sumithira Vasu | 8 | 2015-04-21 | 2020-03-09 |
| Decitabine and Vaccine Therapy for Patients With Relapsed AML Following Allogeneic Stem Cell Transplantation Vaccine - Acute Myelogenous Leukemia | Phase 1 | Withdrawn | University of Louisville | 2015-03-01 | 2017-05-09 | |
| Decitabine and Selinexor in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia decitabine, selinexor, pharmacological study - Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia | Phase 1 | Completed | Bhavana Bhatnagar | 25 | 2014-03-01 | 2017-12-08 |
| AR-42 and Decitabine in Treating Patients With Acute Myeloid Leukemia HDAC inhibitor AR-42, decitabine, laboratory biomarker analysis - Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q) | Phase 1 | Completed | Alison Walker | 13 | 2013-09-17 | 2018-03-14 |
| Differentiation Therapy With Decitabine in Treating Patients With Myelodysplastic Syndrome flow cytometry, DNA methylation analysis, cytogenetic analysis - Chronic Myelomonocytic Leukemia, de Novo Myelodysplastic Syndromes | Phase 1 / Phase 2 | Completed | Case Comprehensive Cancer Center | 25 | 2010-07-01 | 2019-03-04 |
| Decitabine, Vaccine Therapy, and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer decitabine, NY-ESO-1 peptide vaccine, pegylated liposomal doxorubicin hydrochloride - Recurrent Fallopian Tube Cancer, Recurrent Ovarian Epithelial Cancer | Phase 1 | Completed | Roswell Park Cancer Institute | 18 | 2009-04-01 | 2022-08-01 |
| Decitabine With or Without Interferon Alfa-2b in Treating Patients With Unresectable or Metastatic Solid Tumors peginterferon alfa-2b, decitabine, laboratory biomarker analysis - Unspecified Adult Solid Tumor, Protocol Specific | Phase 1 | Terminated | National Cancer Institute (NCI) | 30 | 2009-04-01 | 2014-02-24 |
| Decitabine and Bortezomib in Treating Patients With Acute Myeloid Leukemia bortezomib, decitabine, pharmacological study - Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) | Phase 1 | Completed | National Cancer Institute (NCI) | 19 | 2008-06-01 | 2014-11-07 |
| Vorinostat and Decitabine in Treating Patients With Relapsed, Refractory, or Poor-Prognosis Hematologic Cancer or Other Diseases decitabine, vorinostat, laboratory biomarker analysis - Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q) | Phase 1 | Completed | National Cancer Institute (NCI) | 50 | 2006-06-01 | 2013-01-07 |
| Decitabine With or Without Valproic Acid in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma decitabine, valproic acid, pharmacological study - Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma | Phase 1 | Completed | National Cancer Institute (NCI) | 42 | 2006-03-01 | 2013-06-04 |
| Vorinostat and Decitabine in Treating Patients With Advanced Solid Tumors or Relapsed or Refractory Non-Hodgkin's Lymphoma, Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, or Chronic Myelogenous Leukemia vorinostat, decitabine - Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) | Phase 1 | Completed | National Cancer Institute (NCI) | 80 | 2006-02-01 | 2014-08-27 |
| Decitabine in Treating Patients With Advanced Refractory Solid Tumors or Lymphomas decitabine, pharmacological study, laboratory biomarker analysis - Hematopoietic/Lymphoid Cancer, Unspecified Adult Solid Tumor, Protocol Specific | Phase 1 | Terminated | National Cancer Institute (NCI) | 42 | 2004-09-01 | 2013-01-07 |
| Decitabine and Valproic Acid in Treating Patients With Non-Small Cell Lung Cancer decitabine, valproic acid, pharmacological study - Recurrent Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer | Phase 1 | Completed | National Cancer Institute (NCI) | 25 | 2004-04-01 | 2013-09-30 |
| Decitabine and Valproic Acid in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia or Previously Treated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma decitabine, valproic acid, pharmacological study - Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q) | Phase 1 | Completed | National Cancer Institute (NCI) | 84 | 2004-02-01 | 2013-09-30 |
| Decitabine, Doxorubicin, and Cyclophosphamide in Treating Children With Relapsed or Refractory Solid Tumors or Neuroblastoma decitabine, doxorubicin hydrochloride, cyclophosphamide - Recurrent Neuroblastoma, Unspecified Childhood Solid Tumor, Protocol Specific | Phase 1 | Completed | National Cancer Institute (NCI) | 21 | 2003-12-01 | 2013-09-30 |
| Decitabine in Treating Children With Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia decitabine, pharmacological study, laboratory biomarker analysis - Childhood Acute Myeloblastic Leukemia With Maturation (M2), Childhood Acute Promyelocytic Leukemia (M3) | Phase 1 | Terminated | National Cancer Institute (NCI) | 21 | 2002-12-01 | 2013-01-23 |
| Decitabine in Treating Patients With Myelodysplastic Syndromes or Acute Myeloid Leukemia decitabine, laboratory biomarker analysis, pharmacological study - Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) | Phase 1 | Terminated | National Cancer Institute (NCI) | 36 | 2002-09-01 | 2013-09-30 |
| Decitabine in Treating Patients With Advanced Solid Tumors decitabine, pharmacological study, laboratory biomarker analysis - Male Breast Cancer, Recurrent Bladder Cancer | Phase 1 | Completed | National Cancer Institute (NCI) | 24 | 2001-12-01 | 2013-02-07 |
Leukemia, Myeloid, Acute (11) · Congenital Abnormalities (8) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (3) · Burkitt Lymphoma (2) · Leukemia, Lymphocytic, Chronic, B-Cell (2) · Leukemia, Myelomonocytic, Chronic (2) · Lymphoma, Large B-Cell, Diffuse (2) · Lymphoma, Mantle-Cell (2) · Myeloproliferative Disorders (2) · Anemia, Refractory (1) · Anemia, Refractory, with Excess of Blasts (1) · Blast Crisis (1) · Breast Neoplasms (1) · Breast Neoplasms, Male (1) · Carcinoma, Non-Small-Cell Lung (1)
National Cancer Institute (NCI) (12) · Bhavana Bhatnagar (2) · Alison Walker (1) · Case Comprehensive Cancer Center (1) · Roswell Park Cancer Institute (1) · Ruijin Hospital (1) · Sumithira Vasu (1) · University of Louisville (1)
United States (17) · Canada (2) · China (1)
Bhavana Bhatnagar, DO (2) · Kristie Blum (2) · Alison Walker, MD (1) · Brenda Cooper, MD (1) · David Stewart (1) · Gregory Otterson (1) · Jean-Pierre Issa (1) · Jeffrey Weber (1) · Karen Yee (1) · Kenneth G Lucas, MD (1) · Kunle Odunsi (1) · Mark Minden (1) · Norman Lacayo (1) · Rani George (1) · Sujiang Zhang, MD, PhD (1)
PMID 23660685, PMID 17679729, PMID 22566605, PMID 25621498, PMID 26943915, PMID 31545113
U01CA076576 (4), U01CA062461 (2), U01CA097452 (2), N01CM62203 (1), P30CA016058 (1), R21CA110496 (1), R21CA122270 (1), U01CA062505 (1), U01CA132123 (1)